Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials. Xingxiang Pu,Jiawei Shou,Zemin Xiao,Jun Chen,Maoliang Xiao,Qunyi Guo, Zhongxia Ma,Wei Hong,Qianzhi Wang, Yonghui Wang,Jia Li,Chuangzhou Rao,Jie Weng,Liqin Lu,Lin Wu,Yong FangAdvances in therapy（2025）引用 0|浏览1AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
